Isatuximab Shows Tolerability in Real-World Population With RRMM

Article

In real-world patients with relapsed or refractory multiple myeloma, isatuximab-based regimens were found to be tolerable.

Thomas Martin, MD

Thomas Martin, MD

Regimens containing isatuximab (Sarclisa) demonstrated real-world tolerability in patients with relapsed/refractory multiple myeloma (RRMM), according to first interim results of a study presented at the 2022 International Myeloma Society Annual Meeting.1

Patient baseline characteristics in the observational IONA-MM study (NCT04458831) were consistent with the trials that led to the approvals of Isa-Pd (isatuximab, pomalidomide [Pomalyst], dexamethasone) or Isa-Kd (isatuximab, carfilzomib [Kyprolis], dexamethasone). Investigators reported an expected level of toxicity in IONA-MM, supporting the use of these regimens outside of clinical trials.

“Currently, there is limited real-world evidence available for patients treated with Isa-Pd or Isa-Kd,” Thomas Martin, MD, clinical professor of medicine, associate chief of hematology, and codirector of the myeloma program at UCSF Medical Center.1

The anti-CD38 monoclonal antibody isatuximab was approved for use in the Isa-PD regimen based on positive outcomes from the phase 3 ICARIA-MM (NCT02990338), and in the Isa-Kd regimen based on the phase 3 IKEMA trial (NCT03275285).2,3 The goal of the ongoing noninterventional, multinational IONA-MM study is to collect evidence of the efficacy of these 2 regimens in patients with RRMM in a real-world population that may be different from that of the original trials.

Patients were enrolled both prospectively as well as retrospectively if they had received isatuximab less than 3 months prior to enrollment and treatment was determined by their physician independent of enrollment.

A total of 112 patients across 38 sites in 6 countries between August 13, 2020, and February 22, 2022, were included in this first interim analysis. Of these patients, 81 received at least 1 dose of Isa-Pd and 26 received Isa-Kd, while 5 received other isatuximab-containing regimens.1

Compared with the populations of the ICARIA-MM and IKEMA trials, more patients on IONA-MM were at least 75 years old and more had ISS (International Staging System) stage III disease versus stage I or II disease.1-3 A lower percentage of patients who received Isa-Kd had high-risk cytogenetics (12.5%) compared with those in the IKEMA trial (23.5%).1,3 All groups received a median of 3 prior lines of therapy, except for those on IKEMA who received a median of 2 prior lines.1 The Isa-Pd group included 31.5% of patients who had received at least 4 prior lines of therapy versus 37.0% who had in the ICARIA-MM trial, while 23.1% of those in the Isa-Kd group had received at least 4 lines versus only 1.7% in the IKEMA trial.1-3

In the ICARIA-MM trial, 97.4% of patients had been refractory to their last regimen, but this was only true of 58.0% of those who received the Isa-Pd regimen in the real-world population.1,2 However, more patients (73.1%) in the real-world population were refractory to their last regimen before receiving Isa-Kd versus 49.7% in the IKEMA trial.1,3

For those who received Isa-Pd, the median duration of treatment was 5.4 months (range, 0-18.8) and 79.0% continued to receive isatuximab after the data cutoff.1,2 For those who received Isa-Kd, the median duration was 6.2 (range, 0-10.6), and 74.1% continued to receive isatuximab.1,3

Investigators monitored for treatment-emergent adverse events (TEAEs). Among those who received Isa-Pd, 52 patients (64.2%) had any-grade TEAEs, 36 (44.4%) had grade 3 or more TEAEs, and 21 (25.9%) had serious TEAEs. Among those who received Isa-Kd, 16 (61.5%) patients had any-grade TEAEs, 10 (38.5%) had grade 3 or more TEAEs, and 8 (30.8%) had serious TEAEs.1 All of these rates were significantly lower than in the corresponding phase 3 trial.2,3 There were 4 fatal AEs reported in the Isa-Pd, consisting of 2 cases of sepsis, 1 of septic shock, and 1 failure to thrive.1 One fatal AE occurred in the Isa-Kd arm due to pneumonia.

The most common TEAE in the Isa-Pd population was neutropenia, which occurred in 18 of 81 patients (22.2%), 17 (21.0%) of whom had grade 3 or higher cases.1 In the Isa-Kd population, the most common TEAE was diarrhea, which occurred in 4 of 26 patients (15.4%), none of which were grade 3 or higher.

TEAEs led to treatment discontinuation in 6 (7.4%) of those who received Isa-Pd and 3 (11.5%) of those who received Isa-Kd. Overall, isatuximab-containing regimens appeared to have manageable toxicity in a real-world patient population, with low rates of discontinuation.

The IONA-MM trial will continue to gather data on real-world patients with a target sample size of 1100 patients. Upcoming analyses will include efficacy-related primary end points including overall response rate and progression-free survival.

“In conclusion, the IONA-MM study provides real-world evidence to inform the use of isatuximab in patients with RRMM outside of clinical trials and in a wider patient population,” said Martin.

References:

1. Martin T, Beksac M, Cavo M, et al. Real-world experience with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM): IONA-MM first interim analysis. Poster presented at: 19th Annual International Myeloma Society (IMS) Annual Meeting; August 25-27, 2022; Los Angeles, CA. Abstract P-258.

Recent Videos
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Related Content